22. European Stroke Conference 7 Translational stroke research 9:30 - 9:40 A Three year Follow-Up of Autologous Mononuclear Stem Cell Transplantation in Pa-tients with Chronic Ischemic Stroke P. Srivastava1, R. Bhatia2, S. Mohanty3, S. Kumaran4, A. Bhasin5 All India Institute of Medical Sciences, New Delhi, INDIA1,All India Institute of Medical Sciences, New Delhi, INDIA2, All India Institute of Medical Sciences, New Delhi, INDIA3, All India Institute of Medical Sciences, New Delhi, INDIA4, All India Institute of Medical Scienc-es, New Delhi, INDIA5 Background: The logistics and paradigms in recovery processes after Stroke have led the re-searchers to experiment Stem cell transplantation in neurological conditions. Stem cell (SC) therapy has been envisioned as a therapeutic vehicle to challenge the regenerative potential of brain as they are feasible, multipotent and help in neurofunctional gains thereby promoting re-covery. We previously reported preliminary data of intravenous mononuclear stem cells (MNC) in chronic ischemic stroke with a follow up of 24 weeks and in this study we present long term safety and efficacy with three year follow up (156 week) of the same. Methods: Twenty four (n=24) CIS patients were recruited with the inclusion criteria as: 3 months–2years of stroke onset, hand muscle power (MRC grade) at least 2; Brunnstrom stage of recovery: II-IV. Twelve patients were infused with MNC and twelve acted as controls. All patients were evaluated for safety, i.e. clinical, laboratory and radiological at 24, 78 and 156 weeks (three years). Results and Discussion: We observed that modified Barthel Index showed statistical significant improvement at 156th week (95 % CI : -16.19 to -0.01; p =0.041) follow up in the MNC group as compared to controls (table 1). The 2nd and 3rd quartile for mBI in MNC group was 85 & 87.2 respectively suggesting good functionality and performance of patients in the stem cell group. The impairment scales i.e., Fugl Meyer, ashworth tone scale, MRC for hand muscles (MRC) did not show any significant improvement in three years which is similar to our previ-ous published report. One of the patient reported a dermatologic rash which was found to be unrelated to the cell transplantation. SC therapy may improve recovery after ischemic stroke depending on the inclusion criteria for patients. The occurrence of co morbidities did not differ between the two groups. This report has been optimistic regarding safety as we did not find any cell related side effects / mortality till the last follow up (156th week). 30 © 2013 S. Karger AG, Basel Scientific Programme
Karger_ESC London_2013
To see the actual publication please follow the link above